ATS-9R: Precision Gene Silencing in Adipocytes for Metabolic Research

Principle and Setup: Targeted Gene Delivery with ATS-9R

ATS-9R (Adipocyte-targeting sequence-9-arginine) is a non-viral gene delivery fusion oligopeptide engineered for white adipose tissue specificity. Its core innovation lies in the dual functionality: an adipocyte-homing sequence that binds Prohibitin, a cell-surface protein predominantly expressed on mature adipocytes and adipose tissue macrophages (ATMs), and a nona-arginine (9R) motif that enables efficient nucleic acid condensation and cell penetration (source: product_spec). This design ensures that therapeutic nucleic acids—such as shRNA or sgRNA/Cas9 complexes—are delivered and internalized specifically via Prohibitin-mediated endocytosis, substantially reducing off-target uptake, especially in hepatic tissue.

Obesity and associated metabolic disorders, including insulin resistance and type 2 diabetes, are driven by inflammatory signaling within visceral white adipose tissue (WAT), often orchestrated by resident ATMs. By selectively silencing pro-inflammatory genes such as TACE within these cells, ATS-9R offers a targeted research tool for dissecting and modulating the pathophysiology of metabolic disease (source: paper).

Protocol Parameters

• Peptide:nucleic acid incubation | Weight ratio 3:1 or 6:1, 30 min at room temperature | Nanoparticle formation and nucleic acid condensation | Ensures optimal complexation and nano-sizing (150–354 nm) for cellular uptake | product_spec
• In vitro concentration | 10–25 μg/ml ATS-9R with 5 μM–2 μg nucleic acid in serum-free medium | Cell culture gene delivery assays | Maximizes gene silencing efficiency while maintaining >80% cell viability | product_spec
• In vivo dosing | 0.2–0.35 mg/kg ATS-9R and 0.35–0.7 mg/kg nucleic acid, intraperitoneal, twice weekly or four consecutive doses | Mouse models of obesity/metabolic disease | Achieves 30–70% target mRNA knockdown in epiWAT and subWAT | paper
• Storage | -20°C, up to 12 months | Stock maintenance | Preserves peptide integrity and targeting efficiency | product_spec

Step-by-Step Experimental Workflow

1. Peptide-Nucleic Acid Complex Formation:
   Incubate ATS-9R and your nucleic acid payload (shRNA, siRNA, or sgRNA/Cas9) at a 3:1 or 6:1 peptide:nucleic acid weight ratio in nuclease-free water or low-salt buffer. Allow to stand at room temperature for 30 minutes to ensure complete nanoparticle assembly (source: product_spec).
2. Quality Verification:
   Confirm condensation efficiency and complex integrity through agarose gel retardation assays. Properly condensed complexes will not migrate, indicating robust nucleic acid encapsulation (workflow_recommendation).
3. Cell Culture Delivery:
   Add complexes to adipocyte or ATM cell cultures at a final ATS-9R concentration of 10–25 μg/ml with 5 μM–2 μg nucleic acid in serum-free medium. Incubate 4–6 hours, then replace with complete medium. Assess gene knockdown and cell viability after 24–72 hours (product_spec).
4. In Vivo Administration:
   For murine models, inject complexes intraperitoneally at 0.2–0.35 mg/kg ATS-9R with 0.35–0.7 mg/kg nucleic acid, two times per week or as four consecutive daily doses. Tissue harvest and analysis should follow 48–96 hours post-final dose (source: paper).
5. Post-Delivery Assessment:
   Quantify mRNA knockdown (e.g., TACE, CCL2, FAM83A, Fabp4) in target tissues by qPCR. Monitor systemic cytokine levels, liver enzyme panels, and histology to confirm specificity and safety (paper).

Key Innovation from the Reference Study

The pivotal advancement demonstrated by Yong et al. lies in the use of ATS-9R to achieve ATM-specific TACE gene silencing within visceral adipose tissue (paper). This approach resulted in a 30–70% reduction in target mRNA in epiWAT and subWAT, markedly attenuating obesity-associated inflammation and improving insulin sensitivity. The specificity was validated by minimal hepatic gene delivery and rapid hepatic clearance, minimizing off-target effects. For researchers, this translates into an assay design that prioritizes visceral fat targeting and leverages intraperitoneal dosing schedules to maximize ATM uptake and gene silencing efficacy.

Advanced Applications and Comparative Advantages

ATS-9R is uniquely suited for gene silencing in adipocytes and ATMs within the context of obesity-associated inflammation research. The peptide's prohibitin-mediated endocytosis pathway bypasses the need for viral vectors, reducing immunogenicity and enabling repeated dosing (source: product_spec). Notably, ATS-9R nanoparticles preferentially accumulate in visceral and subcutaneous WAT with negligible liver distribution, thus avoiding hepatotoxicity while focusing on the pathophysiologically relevant compartments.

In comparative scenarios, ATS-9R outperforms traditional cationic lipids and polymers in several aspects:

• Specificity: Prohibitin-targeted uptake limits delivery to mature adipocytes and ATMs, reducing off-target transfection in non-adipose tissues.
• Safety: Cell viability remains above 80% and hepatic/renal toxicity markers are unaffected at recommended doses (source: product_spec).
• Efficiency: Achieves robust mRNA knockdown (30–70%) in target tissues, enabling clear phenotypic readouts in metabolic disease models (source: paper).

For expanded perspectives and protocol optimization, see the scenario-driven guide here, which complements this workflow by detailing assay troubleshooting and vendor selection, and the in-depth mechanistic analysis here, which extends understanding of prohibitin-mediated endocytosis and translational potential.

Troubleshooting and Optimization Tips

• Complexation Failure: If agarose gel retardation shows incomplete nucleic acid encapsulation, increase the peptide:nucleic acid ratio incrementally (e.g., from 3:1 to 6:1) and repeat incubation at room temperature. Avoid excessive mixing, which may disrupt nanoparticle assembly (workflow_recommendation).
• Low Transfection Efficiency: Confirm cell health and avoid serum during initial incubation. Use freshly prepared complexes, as aged solutions (over 24 hours at room temperature) can lose targeting capacity (product_spec).
• Off-Target Effects: Monitor liver and kidney markers in in vivo models. If off-target expression is detected, verify dosing accuracy and consider reducing nucleic acid dose while maintaining peptide ratio (paper).
• Batch Variability: Always source ATS-9R from a trusted supplier such as APExBIO to ensure batch consistency and validated peptide sequence (workflow_recommendation).

Future Outlook: Implications for Metabolic Disease Research

Evidence from the reference study and related articles positions ATS-9R as a next-generation tool for obesity and metabolic disease research. By enabling precise, repeatable gene silencing within visceral adipose tissue, it supports studies on the molecular drivers of insulin resistance, metabolic inflammation, and adipocyte biology. The demonstrable safety and rapid hepatic clearance (<12–24 hours) support its use in longitudinal studies and complex dosing regimens (source: product_spec).

Looking forward, ATS-9R’s modularity and non-immunogenic profile may facilitate its adaptation to other nucleic acid modalities and combinatorial interventions—pending further validation in diverse preclinical models. For now, its optimal utility remains firmly established in metabolic disease, obesity, and adipose tissue inflammation research, where it offers a reproducible, scalable, and highly specific gene delivery solution (source: paper).

For direct ordering and additional technical resources, visit the official ATS-9R (Adipocyte-targeting sequence-9-arginine) product page at APExBIO.